BridgeBio Pharma’s acoramidis shows improved survival data, boosting approval chances. Read why BBIO stock could see gains if ...

The global vutrisiran market, valued at USD 600 million in 2022, is expected to experience substantial growth, reaching an estimated USD 2,087 million by 2033, with a compound annual growth rate (CAGR ...

− Type II Variation Submission Based on the Positive HELIOS-B Phase 3 Study in which Vutrisiran Significantly Reduced the Risk of Death and Cardiovascular Events Relative to Placebo – Alnylam ...

Vutrisiran is the generic name for AMVUTTRA ®, which is currently approved in the European Union (EU) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients ...

(RTTNews) - Alnylam Pharmaceuticals (ALNY) announced the submission of a Type II Variation to the European Medicines Agency for vutrisiran, an investigational RNAi therapeutic in development for ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

Alnylam Pharma has been riding high since revealing top-line results from its HELIOS-B trial of vutrisiran in transthyretin-mediated amyloidosis (ATTR) – but a look at the full data seems to ...

Alnylam Pharmaceuticals ALNY announced that it has submitted a Type II Variation to the European Medicines Agency for vutrisiran, an investigational RNAi therapeutic being developed to treat ATTR ...